Henry Schein (NASDAQ:HSIC) Stock Rating Upgraded by Baird R W

Henry Schein (NASDAQ:HSIC) was upgraded by investment analysts at Baird R W from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday, Zacks.com reports.

Several other research firms have also recently commented on HSIC. Robert W. Baird upgraded Henry Schein from a “neutral” rating to an “outperform” rating and raised their target price for the company from $81.00 to $92.00 in a research report on Monday. Evercore ISI decreased their price target on Henry Schein from $75.00 to $72.00 and set an “in-line” rating for the company in a research note on Tuesday, July 9th. Barrington Research reaffirmed an “outperform” rating and set a $92.00 price target on shares of Henry Schein in a research note on Friday, July 5th. UBS Group decreased their price target on Henry Schein from $82.00 to $80.00 and set a “neutral” rating for the company in a research note on Wednesday, May 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $86.00 price target on shares of Henry Schein in a research note on Friday, June 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $81.67.

Henry Schein Trading Down 1.4 %

Shares of HSIC opened at $69.99 on Monday. The company has a market capitalization of $8.96 billion, a P/E ratio of 23.65, a P/E/G ratio of 1.74 and a beta of 0.87. Henry Schein has a one year low of $60.01 and a one year high of $82.63. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75. The stock has a 50-day moving average price of $68.28 and a 200 day moving average price of $71.92.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, May 7th. The company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.21 billion. During the same quarter last year, the business posted $1.21 EPS. Henry Schein’s quarterly revenue was up 3.7% compared to the same quarter last year. Sell-side analysts forecast that Henry Schein will post 5.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Institutional investors have recently made changes to their positions in the business. Beach Investment Counsel Inc. PA acquired a new stake in Henry Schein during the second quarter worth about $37,000. McGlone Suttner Wealth Management Inc. acquired a new stake in Henry Schein during the fourth quarter worth about $39,000. Blue Trust Inc. grew its position in Henry Schein by 104.2% during the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after buying an additional 475 shares in the last quarter. Mather Group LLC. grew its position in Henry Schein by 16.8% during the second quarter. Mather Group LLC. now owns 1,502 shares of the company’s stock worth $96,000 after buying an additional 216 shares in the last quarter. Finally, Palisade Asset Management LLC acquired a new stake in Henry Schein during the first quarter worth about $113,000. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.